Supercharged immune cells take on Hard-to-Treat blood cancers
NCT ID NCT00881920
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new type of immune therapy for people with certain blood cancers (CLL, lymphoma, or multiple myeloma) that have come back or not responded to treatment. Researchers take a patient's own T cells, add a special receptor that targets a protein called kappa on cancer cells, and also add a growth booster (CD28) to help the cells last longer. The goal is to see if these modified cells are safe and can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Kappa-CD28 T cells (engineered immune cells)
- What this could lead to
- If successful, this could lead to a new treatment option for patients with certain blood cancers that have not responded to standard therapies.
- What could go wrong
- This is an early phase 1 trial with only 54 participants, so results may not apply to everyone. The cells may not last long in the body or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A simple blood test may reveal hidden infertility risk in young cancer survivors